Search

Your search keyword '"Cayla, Guillaume"' showing total 17 results
Start Over Author "Cayla, Guillaume" Publisher wiley-blackwell
17 results on '"Cayla, Guillaume"'

3. Outcomes of 10,312 patients treated with everolimus‐eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium.

Author

Wiebe, Jens, Hofmann, Felix J., West, Nick, Baumbach, Andreas, Carrie, Didier, Bermudez, Eduardo Pinar, Cayla, Guillaume, Hernandez, Felipe Hernandez, de la Torre Hernandez, Jose M., Koning, René, Loi, Bruno, Moscarella, Elisabetta, Tarantini, Giuseppe, Zaman, Azfar, Lober, Christiane, Riemer, Thomas, Achenbach, Stephan, Hamm, Christian W., and Nef, Holger M.

Published
2022
Full Text
View/download PDF

6. PRADOC: a trial on the efficiency of a transition care management plan for hospitalized patients with heart failure in France.

Author

Duflos, Claire, Labarre, Jean‐Philippe, Ologeanu, Roxana, Robin, Marie, Cayla, Guillaume, Galinier, Michel, Georger, Frédéric, Petroni, Thibaut, Alarcon, Clément, Aguilhon, Sylvain, Delonca, Christine, Battistella, Pascal, Agullo, Audrey, Leclercq, Florence, Pasquie, Jean‐Luc, Papinaud, Laurence, Mercier, Grégoire, Ricci, Jean‐Etienne, and Roubille, François

Subjects
HEART failure patients, HOSPITAL patients, PATIENT management
Abstract

Aims: Transition care programmes are designed to improve coordination of care between hospital and home. For heart failure patients, meta‐analyses show a high efficacy but with moderate evidence level. Moreover, difficulties for implementation of such programmes limit their extrapolation. Methods and results: We designed a mixed‐method study to assess the implementation of the PRADO‐IC, a nationwide transition programme that aims to be offered to every patient with heart failure in France. This programme consists essentially in an administrative assistance to schedule follow‐up visits and in a nurse follow‐up during 2 to 6 months and aims to reduce the annual heart failure readmission rate by 30%. This study assessed three quantitative aims: the cost to avoid a readmission for heart failure within 1 year (primary aim, intended sample size 404 patients), clinical care pathways, and system economic outcomes; and two qualitative aims: perceived problems and benefits of the PRADO‐IC. All analyses will be gathered at the end of study for a joint interpretation. Strengths of this study design are the randomized controlled design, the population included in six centres with low motivation bias, the primary efficiency analysis, the secondary efficacy analyses on care pathway and clinical outcomes, and the joint qualitative analysis. Limits are the heterogeneity of centres and of intervention in a control group and parallel development of other new therapeutic interventions in this field. Conclusions: The results of this study may help decision‐makers to support an administratively managed transition programme. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

9. Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non‐ST Elevation Myocardial Infarction registries

Author

Puymirat, Etienne, Bonaca, Marc, Fumery, Maxime, Tea, Victoria, Aissaoui, Nadia, Lemesles, Gilles, Bonello, Laurent, Ducrocq, Grégory, Cayla, Guillaume, Ferrières, Jean, Schiele, François, Simon, Tabassome, and Danchin, Nicolas

Published
2019
Full Text
View/download PDF

11. Early versus delayed invasive strategy for intermediate‐ and high‐risk acute coronary syndromes managed without P2Y12 receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial.

Author

Lemesle, Gilles, Laine, Marc, Pankert, Mathieu, Puymirat, Etienne, Cuisset, Thomas, Boueri, Ziad, Maillard, Luc, Armero, Sébastien, Cayla, Guillaume, Bali, Laurent, Motreff, Pascal, Peyre, Jean‐Pascal, Paganelli, Franck, Kerbaul, François, Roch, Antoine, Michelet, Pierre, Baumstarck, Karine, and Bonello, Laurent

Published
2018
Full Text
View/download PDF

13. Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation.

Author

Collet, Jean-Philippe, Silvain, Johanne, Kerneis, Mathieu, Cuisset, Thomas, Meneveau, Nicolas, Boueri, Ziad, Barthélémy, Olivier, Rangé, Grégoire, Cayla, Guillaume, Belle, Eric Van, Elhadad, Simon, Carrié, Didier, Caussin, Christophe, Rousseau, Hélène, Aubry, Pierre, Monségu, Jacques, Sabouret, Pierre, O'Connor, Stephen A., Abtan, Jérémie, and Saint-Etienne, Christophe

Published
2016
Full Text
View/download PDF

14. First case of invasive meningococcal disease‐induced myopericarditis in a patient with human immunodeficiency virus infection.

Author

Chlilek, Alexandre, Barbar, Saber‐Davide, Stephan, Robin, Barbuat, Claudine, Cayla, Guillaume, Taha, Muhamed‐Kheir, Lavigne, Jean‐Philippe, and Sotto, Albert

Subjects
ABDOMINAL pain, BLOOD, CARDIAC tamponade, CEFOTAXIME, CELL culture, DIARRHEA, ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY, FEVER, HIV-positive persons, CARDIOMYOPATHIES, NEISSERIA meningitidis, PERICARDITIS, PHYSICAL diagnosis, RIFAMPIN, VOMITING, PERICARDIAL effusion, MEDICAL drainage
Published
2021
Full Text
View/download PDF

16. A Case of Cardiomyopathy Induced by Inappropriate Sinus Tachycardia and Cured by Ivabradine.

Author

WINUM, PIERRE‐FRANCOIS, CAYLA, GUILLAUME, RUBINI, MADELEINE, BECK, LIONEL, and MESSNER‐PELLENC, PATRICK

Subjects
*CARDIOMYOPATHIES, *TACHYCARDIA, *HEART beat, *HEART diseases, *THERAPEUTICS, *HEART failure
Abstract

We present the case of a 67-year-old woman with cardiomyopathy induced by inappropriate sinus tachycardia (IST) and a particularly high average heart rate. The patient was resistant and/or intolerant to treatment with conventional rate-slowing medications. We used ivabradine—a specific sinus node If current inhibitor—and successfully lowered the heart rate (33 beats per minute mean heart rate decrease). Symptoms, systolic function, and heart rate variability parameters recovered dramatically. No side effect was noted. We suggest that ivabradine—evaluated in trials to treat stable angina—should be considered as a second-line treatment in patients with very symptomatic and refractory IST. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

17. PRADOC: A Multicenter Randomized Controlled Trial to Assess the Efficiency of PRADO-IC, a Nationwide Pragmatic Transition Care Management Plan for Hospitalized Patients With Heart Failure in France.

Author

Roubille F, Labarre JP, Georger F, Galinier M, Herman F, Berdague P, Nogue E, Petroni T, Delbaere Q, Malak A, Robin M, Prunet E, Leclercq F, Pasquie JL, Papinaud L, Mercier G, Ricci JE, Cayla G, and Duflos C

Abstract

Background: The PRADO-IC (Programme de Retour à Domicile après une Insuffisance Cardiaque) is a transition care program designed to improve the coordination of care between hospital and home that was generalized in France in 2014. The PRADO-IC consists of an administrative assistant who visits patients during hospitalization to schedule follow-up visits. The aim of the present study was to evaluate the PRADO-IC program based on the hypotheses provided by health authorities., Methods and Results: The PRADOC study is a multicenter, controlled, randomized, open-label, mixed-method trial of the transition program PRADO-IC versus usual management in patients hospitalized with heart failure (standard of care group; NCT03396081). A total of 404 patients were recruited between April 2018 and May 2021. The mean patient age was 75 years (±12 years) in both groups. The 2 groups were well balanced regarding severity indices. At discharge, patients homogeneously received the recommended drugs. There was no difference between groups regarding hospitalizations for acute heart failure at 1 year, with 24.60% in the standard of care group and 25.40% in the PRADO-IC group during the year following the index hospitalization (hazard ratio, 1.04 [95% CI, 0.69-1.56]; P =0.85) or cardiovascular mortality (hazard ratio, 0.67 [95% CI, 0.34-1.31]; P =0.24)., Conclusions: The PRADO-IC has not significantly improved clinical outcomes, though a trend toward reduced cardiovascular mortality is evident. These results will help in understanding how transitional care programs remain to be integrated in pathways of current patients, including telemonitoring, and to better tailor individualized approaches., Registration: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT03396081.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results